Antiplatelets In The Wilderness After Mixed Results From DAPT Study
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seems more concerned about mortality than most academics following trial of dual antiplatelet therapy after stenting; AstraZeneca sees potential opening for Brilinta.